



TOLEDO-SPAIN

TOLEDO CONFERENCE
CENTER

16th - 20th May 2017

DND*i*

Drugs for Neglected Diseases *initiative*



Founded by

Prof KP Chang, Prof MA Ozcel, Prof MZ Alzan, Prof Y Ozbel

Goals

- ✓ Re-unite leishmaniacs world-wide to share research thoughts and discoveries
- ✓ Open the forum to individuals and organizations in public and private sectors
- ✓ Promote cross-disciplinary interaction/cooperation from basic research to field work
- ✓ Provide impetus for solving global problems of leishmaniasis

WL has been held quadrennially in endemic countries for 2 decades:

Istanbul 1997

Crete 2001

Palermo 2005

Lucknow 2009

Porto de Galinhas 2013

The organizers



CHAIR

Jorge Alvar

Head of the Leishmaniasis Program

Drugs for Neglected Diseases initiative (DNDi)

Geneva- Switzerland



MINISTERIO DE ECONOMÍA Y COMPETITIVIDAD



Instituto de Salud Carlos III

CO- CHAIR

Javier Moreno

Director WHO CC-Leishmaniasis

Instituto de Salud Carlos III

Madrid-Spain

ORGANIZING COMMITTEE

Fabiana Alves (DNDi)

Byron Arana (DNDi)

Ricardo Moreno (ISCIII)

WL
scientific
committee

Spanish
scientific
committee

Ad hoc
scientific
committee

Organizers
DNDi-ISCIII scientific
committee

The organizers




Fundraising and sponsorship

Logistics

Secretariat and web page

WL6 scientific agenda



WL6 scientific agenda

		Tu 16 May	We 17 May	Th 18 May	Fr 19 May	Sa 20 May
8:30 - 9:30	P O S T E R E X H I B I T I O N	Plenary talk				
9:30 - 10:30		Session 1	Registration Welcome remarks Opening conference			
10:30 - 11:30		Session 2	1 Signal transduction in leishmaniasis			
11:30 - 12:30			2 VL treatment and combos			
14:00 - 15:00			3 Biology informing epidemiology & control			
14:00 - 15:00		Session 3	4 New methods for gene and genome editing			
			5 Drug Resistance			
			6 Operational Research			
15:00 - 16:30		Oral presentations	A.- Basic			
16:30 - 17:30			B.- Applied			
16:30 - 17:30						
17:30 - 19:00	Satellites	XXX				
16:00 - 19:00	Symposia	A road map for oral drugs (DNDi)				

Auditorium (950 p);
 Room C (150 p);
 Room D (120 p);
 Plenary (in Auditorium);
 Satellites (in Room C);
 Symposia (in Room D);
 Oral presentations

Room A (58 p): speakers; Room B (58 p): organizers;

WL6 scientific agenda

		Tu 16 May	We 17 May	Th 18 May	Fr 19 May	Sa 20 May
8:30 - 9:30	P O S T E R E X H I B I T I O N	Plenary talk	How leishmania is killed, how leishmania kills			
9:30 - 10:30		Session 1	Registration Welcome remarks Opening conference	7 Retooling in macrophage-parasite interaction 8 Biomarkers & RDTs 9 Tools for epidemiology. Asymptomatics		
10:30-11:30						
11:30-12:30		Session 2	1 Signal transduction in leishmaniasis	10 Myeloid subsets in macrophage-leishmania outcome		
			2 VL treatment and combos	11 Immunosuppression and leishmaniasis		
			3 Biology informing epidemiology & control	12 Vector and Leishmania interactions		
14:00-15:00		Session 3	4 New methods for gene and genome editing	13 Microbiome		
			5 Drug Resistance	14 Drug discovery		
			6 Operational Research	15 Outbreak assessment & surveillance		
15:00-16:30		Oral presentations	A.- Basic B.- Applied	A.- Basic B.- Applied		
16:30-17:30		Poster presentation				
17:30-19:00	Satellites	XXX	XXX			
16:00-19:00	Symposia	A road map for oral drugs (DNDi)	Consensus for preclinical vaccine assay standardisation			
		Auditorium (950 p); Room C (150 p); Room D (120 p); Plenary (in Auditorium); Satellites (in Room C); Symposia (in Room D); Oral presentations				
		Room A (58 p): speakers; Room B (58 p): organizers;				

WL6 scientific agenda

		Tu 16 May	We 17 May	Th 18 May	Fr 19 May	Sa 20 May	
8:30 - 9:30	P O S T E R E X H I B I T I O N	Plenary talk	How leishmania is killed, how leishmania kills	Can VL be eliminated in the Indian subcontinent?			
9:30 - 10:30		Session 1	Registration Welcome remarks Opening conference	7 Retooling in macrophage-parasite interaction	16 Beyond Th1/th2 paradigm		
				8 Biomarkers & RDTs	17 CL species diagnostics		
				9 Tools for epidemiology. Asymptomatics	18 New vector control measures		
10:30-11:30			Poster presentation				
11:30-12:30		Session 2	1 Signal transduction in leishmaniasis	10 Myeloid subsets in macrophage-leishmania outcome	19 Molecular basis on virulence and tropism		
			2 VL treatment and combos	11 Immunosuppression and leishmaniasis	20 CL treatment & pipeline drugs		
			3 Biology informing epidemiology & control	12 Vector and Leishmania interactions	21 What's new on reservoirs?		
14:00-15:00		Session 3	4 New methods for gene and genome editing	13 Microbiome	22 Advances in immunopathology		
			5 Drug Resistance	14 Drug discovery	23 MCL & DCL		
		6 Operational Research	15 Outbreak assessment & surveillance	24 WHO control Programs			
15:00-16:30	Oral presentations	A.- Basic	A.- Basic	A.- Basic			
16:30-17:30		B.- Applied	B.- Applied	B.- Applied			
16:30-17:30		Poster presentation					
17:30-19:00	Satellites	XXX	XXX	XXX			
16:00-19:00	Symposia	A road map for oral drugs (DNDi)	Consensus for preclinical vaccine assay standardisation	Consensus for preclinical drug assay standardisation			
<p> ■ Auditorium (950 p); ■ Room C (150 p); ■ Room D (120 p); ■ Plenary (in Auditorium); ■ Satellites (in Room C); ■ Symposia (in Room D); ■ Oral presentations Room A (58 p): speakers; Room B (58 p): organizers; </p>							

WL6 scientific agenda

		Tu 16 May	We 17 May	Th 18 May	Fr 19 May	Sa 20 May	
8:30 - 9:30	P O S T E R E X H I B I T I O N	Plenary talk	How leishmania is killed, how leishmania kills	Can VL be eliminated in the Indian subcontinent?	Conflicts and leishmania		
9:30 - 10:30		Session 1	Registration Welcome remarks Opening conference	7 Retooling in macrophage-parasite interaction	16 Beyond Th1/th2 paradigm	25 Canine leishmaniasis (Basic research)	
				8 Biomarkers & RDTs	17 CL species diagnostics	26 Advances in Immunotherapy	
				9 Tools for epidemiology. Asymptomatics	18 New vector control measures	27 Fuenlabrada outbreak	
10:30-11:30			Poster presentation				
11:30 - 12:30		Session 2	1 Signal transduction in leishmaniasis	10 Myeloid subsets in macrophage-leishmania outcome	19 Molecular basis on virulence and tropism	28 Bioimaging	
			2 VL treatment and combos	11 Immunosuppression and leishmaniasis	20 CL treatment & pipeline drugs	29 Physical methods & natural (phyto) products for CL treatment	
			3 Biology informing epidemiology & control	12 Vector and Leishmania interactions	21 What's new on reservoirs?	30 Leishmaniasis vaccine pipeline	
14:00-15:00		Session 3	4 New methods for gene and genome editing	13 Microbiome	22 Advances in immunopathology	31 Delivery systems for drug/ vaccines	
			5 Drug Resistance	14 Drug discovery	23 MCL & DCL	32 PKDL	
		6 Operational Research	15 Outbreak assessment & surveillance	24 WHO control Programs	33 Modelling transmission & control		
15:00-16:30	Oral presentations	A.- Basic	A.- Basic	A.- Basic	A.- Basic		
16:30-17:30		B.- Applied	B.- Applied	B.- Applied	B.- Applied		
16:30-17:30		Poster presentation					
17:30-19:00	Satellites	XXX	XXX	XXX	XXX		
16:00-19:00	Symposia	A road map for oral drugs (DNDi)	Consensus for preclinical vaccine assay standardisation	Consensus for preclinical drug assay standardisation	Advocating for the future		
	Auditorium (950 p); Room C (150 p); Room D (120 p); Plenary (in Auditorium); Satellites (in Room C); Symposia (in Room D); Oral presentations Room A (58 p): speakers; Room B (58 p): organizers;						

WL6 scientific agenda

		Tu 16 May	We 17 May	Th 18 May	Fr 19 May	Sa 20 May	
8:30 - 9:30	P O S T E R E X H I B I T I O N	Plenary talk	How leishmania is killed, how leishmania kills	Can VL be eliminated in the Indian subcontinent?	Conflicts and leishmania	Access to treatment	
9:30 - 10:30		Session 1	Registration	7 Retooling in macrophage-parasite interaction	16 Beyond Th1/th2 paradigm	25 Canine leishmaniasis (Basic research)	34 Animal models
			Welcome remarks	8 Biomarkers & RDTs	17 CL species diagnostics	26 Advances in Immunotherapy	35 Canine leishmaniasis (Clinical aspects)
			Opening conference	9 Tools for epidemiology. Asymptomatics	18 New vector control measures	27 Fuenlabrada outbreak	36 Platforms for research & control
10:30- 11:30			Poster presentation				
11:30 - 12:30		Session 2	1 Signal transduction in leishmaniasis	10 Myeloid subsets in macrophage-leishmania outcome	19 Molecular basis on virulence and tropism	28 Bioimaging	Awards & Closing conference
			2 VL treatment and combos	11 Immunosuppression and leishmaniasis	20 CL treatment & pipeline drugs	29 Physical methods & natural (phyto) products for CL treatment	
			3 Biology informing epidemiology & control	12 Vector and Leishmania interactions	21 What's new on reservoirs?	30 Leishmaniasis vaccine pipeline	
14:00- 15:00		Session 3	4 New methods for gene and genome editing	13 Microbiome	22 Advances in immunopathology	31 Delivery systems for drug/ vaccines	
			5 Drug Resistance	14 Drug discovery	23 MCL & DCL	32 PKDL	
		6 Operational Research	15 Outbreak assessment & surveillance	24 WHO control Programs	33 Modelling transmission & control		
15:00- 16:30	Oral presentations	A.- Basic	A.- Basic	A.- Basic	A.- Basic		
		B.- Applied	B.- Applied	B.- Applied	B.- Applied		
16:30- 17:30		Poster presentation					
17:30- 19:00	Satellites	XXX	XXX	XXX	XXX		
16:00- 19:00	Symposia	A road map for oral drugs (DNDi)	Consensus for preclinical vaccine assay standardisation	Consensus for preclinical drug assay standardisation	Advocating for the future		

The collaboration



Articles submitted during 2016

Hot topics parallel sessions



WL6 special collection

PLOS One
PLOS NTD
LOS Pathogens

Call for papers May 2016



Prices to 20 researchers: ceremony during congress

The venue: Toledo

The city of three cultures

World heritage city UNESCO 1986

El Greco



Modern
congress
facilities

Spain's gastronomic capital 2016

Proximity to Madrid

Save the date

worldleish2017.org

Deadline
for posters
30 Nov.
2016



TOLEDO-SPAIN
TOLEDO CONFERENCE
CENTER
16th - 20th May 2017



In collaboration with

